Index

ABCC6 gene mutations, 132–133
ABCD2 score, 61, 576–577
ABCD3-I score, 576
abciximab, 165, 179
Abciximab in Emergent Stroke Treatment Trial II (ABESTT-II), 179
abdominal imaging, 579
Abercrombie, John, 4
Abercrombie stroke trials, 165
acetazolamide, 168
Ackerman, Robert, 6
activated partial thromboplastin time (aPTT), 112
activity-based brain repair therapies, 613
acute posterior, multifocal, placoid-pigment epiphiteliopathy, 406
Adams, Raymond, 6
AIDS, 394, 398
arteriopathy associated with, 399
air embolism, 349–350
Alberta Stroke Program Early CT Score (ASPECTS), 81
alcohol use risk factor for stroke, 575
ALDH2 gene, 137–138
alexia without agraphia, 276
Alzheimer’s disease, 104, 135, 396, 579
amantidine, 615
Amareno, Pierre, 336
amaurosis fugax, 218, 231
ambaritaly cardiac rhythm monitoring, 7
amebic infections of the CNS, 400
amphetamin, 189, 408, 482
ICH related to, 484–485
therapeutic use, 615
Amplatz PFO Occluder, 173, 336
anatomy of stroke, 19
cervico-cranial artery walls, 31
common locations for ICH, 41
common sites of intracranial aneurysms, 38–39
distribution of brain pathology, 39–41
distribution of embolic pathology, 38
distribution of ICH pathology, 38
distribution of ischemic pathology, 39–40
distribution of SAH pathology, 38–39
distribution of thrombosis pathology, 36–38
distribution of vascular pathology, 36–39
importance of identifying the location, 25–26
normal arterial circulation, 26–31
venous and dural sinus anatomy, 31–34
anind, 112, 160, 168
anemia, 170, 415, 546
anemic-hypoxic brain injury, 365
aneurysm consequence sites of intracranial aneurysms, 38–39
treatment of unruptured aneurysms, 454
aneurysmal SAH antiplatelet agents, 452
blood pressure control, 452
cardiac and pulmonary abnormalities, 451
causes, 439
causes of rupture, 440
clinical findings, 441–443
clinical severity scales, 443
complications and their management, 447–452
consequences of aneurysm rupture, 439
delayed cerebral ischemia (vasoconstriction), 448–450
diagnostic testing, 443–446
computed tomography (CT), 443–444
CT perfusion scanning, 446
diffusion and perfusion MR scanning, 446
digital subtraction cerebral angiography, 445–446
lumbar puncture, 445
magnetic resonance imaging (MRI), 444–445
SPECT, 446
transcranial Doppler ultrasound (TCD), 446
xenon-enhanced CT, 446
differential diagnosis, 446
diagnostic testing, 443–446
eoclinic abnormalities, 451–452
diagnostic testing, 443–446
differential diagnosis, 446
diagnostic testing, 443–446
diffusion and perfusion MR scanning, 446
digital subtraction cerebral angiography, 445–446
intracranial dissections, 390
occlusion or severe stenosis, 239–241
anterior choroidal arteries (AChA), 27–28
occlusion, 243–244
anterior circulation, 28
large artery occlusive disease, 217–244
anterior inferior cerebellar artery (AICA), 31
antiplatelet therapies for specific vessel sites, 180
antipsychotic drugs, 338
antithrombin, 112
antithrombin deficiency, 416
antithrombin III, 45
Antoni’s syndrome, 276–277
aorta source of brain emboli, 336–337

© in this web service Cambridge University Press
www.cambridge.org
Aortic Arch Related Cerebral Hazard (AARCH) trial, 180, 337
aortic conditions
risk of stroke, 580
aortic regurgitation, 324
aortic valve disease
source of brain emboli, 323–324
aphasia
therapies for, 617
apixaban, 9, 176, 177, 321
APOE gene, 137, 139
apoplexy, 2
apoprtosis, 43
APP gene mutation, 135
apraxia of gaze, 278
aquried hemophilia, 416
argatroban, 165, 176
ARISTOTLE trial, 321
arterial circulation
normal circulation, 26–31
arterial dissections, 37–38, 386
anticoagulant indications and timing, 174–176
carotid artery dissections in the neck, 386–389
intracranial dissections, 390
management, 390–391
vertebral artery dissections in the neck, 389–390
arterial sources of brain emboli, 341–342
arteries
composition of cervico-cranial artery walls, 31
morphology of extracranial arteries, 31
morphology of intracranial arteries, 31
arterovenous malformations (AVMs), 454–455
clinical symptoms and signs, 458–460
diagnosis, 460
imaging findings, 460
locations, 458
pathogenesis, 456–457
prognosis, 461
treatment, 462–464
arteritis, 20
as cause of stroke, 396
bacterial infections, 397–399
caused by infections, 397–400
fungal infections, 397–399
parasitic infections, 400
viral infections, 399–400
Aspergillus infection, 398–399, 551
aphasia
complication in stroke patients, 599–600
aspirin, 165, 169, 177
anticoagulant properties, 9
Asymptomatic Carotid Artery Study, 228
ataxic hemiparesis, 293
Athens Stroke Registry, 279–280
atherosclerosis, 20
sites of atherosclerotic narrowing, 36–37
atherosclerotic plaques, 8, 43–44
atherothrombosis, 45
afibases published in the nineteenth century, 4
atorvastatin, 183, 184, 568
APTT gene mutation, 419
atrial fibrillation, 171, 172–173
risk of brain embolism, 318–322
atrial septal aneurysm (ASA), 335
atrial septal defects, 20, 173–174
source of brain emboli, 318
atromid, 169
autosomal dominant type 1 porencephaly, 135
AX200 for Ischemic Stroke (AXIS) study, 616
A xenfeld-Rieger syndrome, 136
B19 virus, 399
Bubhikan, Viken, 6
bacterial causes of vasculitis, 397–399
bacterial endocarditis, 173, 579
Baldf’s syndrome, 278, 372–373
balloon angioplasty, 12–13, 151, 153
balloon catheterization, 12
Baltimore-Washington Young Stroke Study, 526
Barrett, Henry, 10
Baron, Jean-Claude, 6
Bartleson’s syndrome, 410
Bartonella henselae infection, 598, 399
basic fibroblastic growth factor (bFGF), 616
BASICS Registry, 270
basilar arteries, 28–31
bilateral brainstem infarction, 266–273
dissection of the basilar artery, 273
intracranial dissections, 390
unilateral brainstem infarction, 273
vasculitis, 400
Basilar Artery International Cooperation Study (BASICS), 270
Bayes’ theorem, 56–57
bedside tests of high-level cortical function, 71
Behçet’s disease, 405, 546
Besancon Stroke Registry, 279–280
beta-bFG+erythropoietin in acute stroke (BETAS) study, 616
beta-human chorionic gonadotropin (hCG), 616
Binswanger’s disease, 301, 302
biomarkers for vascular disease, 580–581
bleeding diatheses, 24
bleeding disorders, 416
hereditary, 115
iatrogenic, 115
blood abnormalities in intracerebral hemorrhage, 115
in subarachnoid hemorrhage, 115
role in stroke, 110
blood abnormalities in ischemic stroke, 110–114
additional blood measurements, 113–114
albumin and globulin levels, 112
antiphospholipid antibodies (APLAs), 113
blood sugar levels, 113
blood viscosity, 111–112
coaulation factors, 112–113
coaulation testing, 112–113
ehrthrocytes, 110–111
fibrinogen, 111–112
leukocytes, 111
lipoprotein levels, 112
platelets, 111
testing that reflects stroke risk, 114
blood flow disorders, 416–417
blood sugar levels, 113
blood viscosity, 111–112
disorders, 416–417
reduction, 168–169
Blumgart, Dr Herman, 2
body-weight supported treadmill training (BWSTT), 613orderzone infarcts and hemodynamic impairment, 372–373
borderzone regions, 22, 39–40
spinal cord, 535
Borrelia infection, 398
Boston Stroke Society, 6
Boyle, Robert, 3
bradycardia-tachycardia syndrome, 322
brain
autoregulation of cerebral blood flow, 42
energy and oxygen requirements, 41–42
increasing resistance to ischemia, 181–183
normal metabolism and blood flow, 41–42
brain-derived neurotrophic factor (BDNF), 616
brain edema
causes, 184
complications in stroke patients, 595–596
effects of, 184
management, 346
reducing or limiting the size of ICH, 184–186
related to brain infarct, 84
thrombosis pathophysiology, 47
treatment, 186–188
brain embolism
clinical findings related to the recipient artery, 312–314
imaging related to the recipient artery, 315–318
laboratory findings related to the recipient artery, 315–318
likelihood of causing stroke and infarction, 312
occurrence of embolic particles, 312
See also embolism.
brain embolism treatment
antithrombotic treatment, 345
augmenting brain blood flow, 345
chemical or mechanical clot removal, 344
goals of, 343
neuroprotection, 345
opening of blocked recipient arteries, 343–344
reperfusion, 343–345
thrombolysis, 344
treatment strategies, 343
brain embolus sources
air embolism, 349–350
aorta, 336–337
aortic valve disease, 323–324
arrhythmias, 318–322
arterial sources, 341–342
atrial fibrillation, 318–322
cardiac septal lesions, 333–336
cardiac sources, 318–336
cardiac surgery complications, 338–341
cardiac tumors, 332–333
cardiac valve disease, 322–326
cardiac valve strands, 328–331
coronary artery disease, 331–332
fat embolism, 347–349
foreign body embolism, 330–331
imaging of potential donor sources, 342–343
infective endocarditides, 326–328
laboratory evaluation of potential donor sources, 342–343
materials that originate outside the vascular system, 347–351
mitral annulus calcification (MAC), 325
mitral valve prolapse (MVP), 324–325
myocardial infarction, 331–332
myocardinopathies, 332

© in this web service Cambridge University Press
www.cambridge.org
non-infective fibrous and fibrinous endocardial lesions, 328–331
paradoxical embolism, 333–336
patent foramen ovale, 333–336
prosthetic cardiac valves, 325–326
range of sources, 318
rheumatic mitral valve disease, 322–323
sick sinus syndrome, 322
sinus node dysfunction, 322
tumor embolism, 350
types of embolic materials, 318
brain embolus treatment
brain edema management, 346
chronic prophylactic treatment to prevent reembolization, 346–347
mass effect management, 346
brain function
EEG (electroencephalography), 115
brain lesion investigation, 82–83
infarcts, 83–84
brain-machine computer interfaces, 190
brain repair strategies
activity-based therapies, 613
brain stimulation therapies, 614–615

cognitive strategies, 617

emerging neural repair strategies, 613
for aphasia, 617
for cognitive deficits, 617
for visual field defects, 617
gait training, 72
growth factors, 616
mental activity, 617
movement observation, 617
pharmacological therapies, 615
principles of brain repair, 617–618
robot-based therapies, 613–614
sensory stimulation, 614
stem cell therapies, 615–616
telerhabilitation, 614
brain shifts caused by mass effects, 48–49
brain small vessel disease with Axenfeld–Rieger anomaly, 135
brain small vessel disease with hemorrhage, 135
brain stimulation therapies, 614–615

brainstem
bilateral infarction, 266–273
unilateral infarction, 273
branch artery disease, 273
lacunar infarction; lacunar stroke
brightness modification
(B-mode) ultrasound, 87–88
Bright’s atlas, 4
bronnocriptine, 189, 615
Bruckmann, Helmut, 11
Buergers disease, 404
CADISP consortium, 138
calcineurin bank lesions, 277–279
calcific aortic stenosis, 173
calcium channel blockers, 168
California encephalitis virus, 399
Canadian–American Ticlopidine Study (CATS), 178
Canadian Pediatric Ischemic Stroke Registry, 513
cancer and cerebral venous thrombosis (CVT), 545–546
stroke related to, 416
candidiasis, 399
cannabis, 417
carbidopa, 615
carbon dioxide (CO₂) vasodilation property, 167
carbon monoxide (CO) poisoning, 375
cardiac abnormalities complications of stroke, 598–599
cardiac arrest
coronary angiography and recanalization, 366
critical care approach, 377–378
goal-directed hemodynamic optimization, 366–367
immediate post-resuscitation strategies, 366–367
pathophysiology of brain injury, 364–365
post-cardiac arrest encephalopathy, 364
prognostication following, 369–372
targeted temperature management, 366
cardiac conditions
risk of stroke, 580
cardiembol risk evaluation, 105–109
cardiembolopathy, 376–377
cardiembol evaluation imaging, 105–109
cardiac myxoma, 173, 332-333
cardiogenic embolism
anticoagulant indications and timing, 172–174
cardiogenic embolism
ambulatory monitoring, 7
cardiac septal lesions source of brain emboli, 333–336
cardiac surgery complications
sources of brain emboli, 338–341
cardiac tumors sources of brain emboli, 332–333
cardiogeni embolism, 66
caregivers
challenges of caring for a stroke patient, 603
carotid allegro, 387
Carotid and Vertebral Transluminal Angioplasty Study (CAYTAS), 152
carotid arteries
dissections in the neck, 386–389
occlusion, 3, 7
origin of the name, 3
Carotid Occlusion Study, 167
Carotid Occlusion Surgery Study (COSS), 167, 225
carotid siphon, 26, 36
Carroll, Lewis, 10
cat-scratch disease, 398, 399
catheter angiography, 7

cathectom basal ganglia, 161
cather digital subtraction angiography, 104–105
caudate nucleus infarcts, 241–243
signs and symptoms of ICH, 491
cavernous angiomas, 455–456

diagnosis, 460
imaging findings, 460
locations, 458
of the spine, 359–360
prognosis, 461–462
treatment, 462–464

cavernous sinus thrombosis, 549–551
cavernous sinuses, 33
CBS (cystathionine beta-synthase) gene mutation, 131
CDC5 L gene, 137, 138
cellular abnormalities of the blood, 415
cerebellar vein thrombosis, 549–551, 553
cerebral amyloid angiopathy (CAA), 38, 104, 302, 395–396
familial forms, 135
microbleeds, 579
risk of ICH, 486

cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 129–130, 288, 302, 419, 512, 513
cerebral autosomal reccessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), 130–131, 288, 419
cerebral venous sinus thrombosis imaging, 97
cerebral venous thrombosis (CVT), 45
anticoagulant indications and timing, 174
clinical findings, 547–549
decreased level of consciousness, 549
definition, 544
demography, 544
development of ideas about, 544
diagnosis, 553–557
distribution of venous structure involvement, 549–553
dural sinus thrombosis, 544
etiologies, 544–546
abnormalities of the blood and coagulation system, 546
congenital thrombophilia, 546
hormonal changes, 545
infections, 545
neoplasms, 545–546
pregnancy and postpartum, 545
systemic conditions, 546
findings related to specific locations, 549–553
focal neurological signs and symptoms, 549
frequencies of various causes, 546
headache symptom, 548–549
imaging and neuroradiological investigations, 553–557
management after the acute phase, 560
onset and course, 547–548
outcome, 559–560
pathophysiology, 546–547
seizures, 549

treatment, 557–560
cerebellar hemorrhages signs and symptoms, 497–499
Cerebri Anatomie, 3
cerebrovascular ataxia
(CBAVATAS), 152
Cerebrovascular disease definition, 19
Cervical Artery Dissection in Stroke Study (CADISS-NR), 229
Chagas disease, 400
CHANCE trial, 179
Charcot-Bouchard aneurysms, 481
Cheyne, John, 4
children (1 month to 18 years).
See pediatric stroke
## Index

**Chinese Intracranial Atherosclerosis Study group**, 289
chronic basal meningitis, 398
chronic penetrating artery disease clinical findings, 302
historical background, 301
imaging, 302–303
pathogenesis, 303–304
pathology, 301–302
treatment, 304
chronic white matter abnormalities
pathogenesis, 303–304
chronic white matter microbleeds treatment, 304
Churchill, Winston, 1
Churg–Strauss syndrome, 401
chylomirica, 112, 114
cilostazol, 169, 177–178
citoline, 182
cliodigrel, 169, 178–179
Clodigrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events (CHARISMA) trial, 179
Clodigrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial, 178
CLOSURE I trial, 336
clot retrieval devices, 13, 161, 162–165
coeagulation cascade, 45
cogulation factors, 112–113
cogulation system activation, 44–46
cogulation testing, 112–113
coarctation of the aorta, 440
cocaine use, 408–409, 482
and neonatal stroke, 515
ICH related to, 485
stroke related to, 526
coeccidoidal meningitis, 399
*Coccidioides* infection, 398
Cogan’s syndrome, 405
cognitive defects therapies for, 617
cognitive therapies, 617
Cohorts of Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, 137, 138
coils use to obliterate aneurysms, 12
*COL1A1* gene mutations, 136
*COL1A2* gene mutations, 136
*COL3A1* gene mutation, 133
*COL4A1* gene, 139
*COL4A1* gene mutations, 135–136, 288
*COL4A1* syndrome, 131, 135–136, 421
*COL4A2* gene, 139
cold-pressor test, 482
collagen vascular diseases, 401–402
collateral circulation, 3, 19
increasing blood flow in, 167–169
influence on ischemic tissue survival, 46
color Doppler flow imaging (CDFI), 89–90
color Doppler imaging, 109
coma, 367–368
common carotid arteries (CCAs), 26, 29, 218
communicating hydrocephalus, 50
complementary intrinsic coagulation system, 170
complications of stroke aspiration, 599–600
brain edema, 595–596
cardiac abnormalities, 598–599
causes of death, 594
challenges for caregivers, 603
contractures, 601
deep vein thrombosis, 597–598
depression, 602–603
fatigue, 602
gastrointestinal bleeding and other complications, 601
immobility and its complications, 601–602
medical complications, 597–600
metabolic disorders, 600
neurological complications, 594–597
nutritional disorders, 600
osteoepenia, 601–602
osteoeporosis, 601–602
peripheral nerve injuries, 601
pneumonia, 599–600
pressure decubitus ulcers, 601
prevention of complications, 603
psychological effects of stroke, 602–603
pulmonary embolism, 597–598
seizures, 596–597
shoulder pain, 601
stroke progression or recurrence, 594–595
swallowing abnormalities, 599–600
types and frequency, 594
urinary incontinence, 600–601
urinary tract infections, 600–601
compounded ultrasound imaging, 90
congenital hemiplegia, 515
congenital thrombophilia, 546
congestive heart failure, 546
congophilic angiopathy, See cerebral amyloid angiopathy (CAA)
conjugate-gaze paralysis, 72
connective tissue heritable disorders, 392–393
constraint-induced movement therapy (CIMT), 613
consumptive coagulopathies, 111
continuous-wave (CW) Doppler, 88–89
contractures in stroke patients, 601
Cooperative Study of Intracranial Aneurysms and Subarachnoid Hemorrhage, 440
Copenhagen City Heart Study, 578
Coronary artery atherosclerosis risk factor for stroke, 575–576
Coronary artery bypass graft (CABG) surgery
source of brain emboli, 338–341
Coronary artery disease source of brain emboli, 331–332
Coronary Artery Surgery Study (CASS), 331
cortical vein thrombosis, 549–551, 552–553
corticosteroids, 187, 399
cough and cold remedies
ICH risk with phenylpropanolamine (PPA), 485–486
coumadin, 9, 175
coumarin, 9
coxackie 9 virus, 399
CREST trial, 152, 223, 228
critical care management of brain injury
basic critical care, 375–376
neurocritical care, 376
Crohn’s disease, 416, 546
CRP (C-reactive protein) levels correlation with stroke risk, 114, 581
Crueviller’s atlas, 4
cryptococcosis, 399
cryptococcus infection, 398
CYSTAL AF trial, 320
CT3 gene mutation, 135
CT (computed tomography), 7–8
multimodal protocols, 100–101
perfusion imaging, 97, 100–101
scans of vascular lesions, 93
stroke mechanism investigation, 78–79, 80–82
xenon CT, 101
CT angiography (CTA), 8, 96–97, 217
CT venography (CTV) cerebral venous sinus thrombosis, 97
Cushing response, 480, 598
Cushing’s ulcers, 601
cyclandelate, 167
CYP2C9 gene, 172
cystic medial necrosis, 386
cysticercosis, 400
cytoid bodies, 70
cytomegalovirus, 399
cytotoxic edema, 47
dabigatran, 9, 176, 321
Danaparoid, 174–175
Danish Aneurysm Study, 441
Danish Nurse Study, 577
data banks of stroke data, 8
Davis, Steven, 6
d-limer level diagnosis, 557
De Humani Corpis Fabrica, 3
De Sedibus et Causis Morborum per Anatomam Indagati, 3
decompensative hemicraniectomy, 187
decubitus ulcers, 600, 601
deep vein thrombosis, 597–598
depression and Subarachnoid Hemorrhage, 440
depression in stroke patients, 602–603
desmoteplase, 159, 161
DEFUSE-2 study, 233
degenerative change, 152
dehydration
thrombosis risk, 546
Dejong, Russell, 1
del Zoppo, Gregory, 1
Demographic risk factors for stroke, 569
Depression in stroke patients, 602–603
developmental venous anomalies (DVA), 455
diagnosis, 460
imaging findings, 460
prognosis, 462
treatment, 462–464
dexamethasone-suppression test, 602
diabetes
stroke risk, 573–574, 581
diabetic ketoacidosis, 399
diagnosis of stroke, 19
accompanying symptoms, 66
activity at onset, 63
approach to localization, 72
bedside tests of high-level cortical function, 71
common localization patterns, 72–74
comparison with stroke registry or stroke data base information, 74–75
eye early course of development of the deficit, 63–66
evaluation of motor function, 72
evaluation of somatosensory functions, 72
evaluation of visual and oculomotor function, 71–72
findings from examination of the eyes, 69–70
findings from examination of the heart, 66
findings from examination of the vascular system, 66–69
history of TIA’s, 61–63
identification of the mechanism, 55
inductive method, 56
information used for diagnosis, 55
level of alertness, 71
localization and detection of vascular lesions, 66–70
localization information from the neurological examination, 71
localization of the lesion(s), 55
observation of gait, 72
patient risk factors, 57–60
patient vignette, 55, 59–60, 73–74
pattern-matching technique, 56
prior cerebrovascular symptoms, 61–63
sequential hypothesis
 generation and testing, 56
technical advances, 7–8
use of Bayes’ theorem, 56–57
use of ecological data, 57–60
use of incidence data and probabilities, 56–57
diagnostic tests
 approach to selection of tests, 78
blood abnormalities and their effects, 110–115
brain lesion location and characteristics, 82–86
cause of the brain lesion, 78–82
genetic testing of stroke patients, 115–116
identifying seizures in stroke patients, 115
sequence of diagnostic questions, 78
stroke mechanism investigation, 78–82
vascular lesion location and characteristics, 86–110
Diamox (acetazolamide), 168
diachisis, 103–104, 609
dicumarol, 9
differential diagnosis
posterior circulation ischemia, 279–280
Diffusion and Perfusion Imaging Evaluation For
Understanding Stroke Evolution (Défuse) trial, 159
diffusion-perfusion mismatch, 150
diffusion-weighted imaging (DWI), 79
dilatative arteriopathy, 393–395
dipridamole, 169, 177–178
direct acting oral anticoagulants (DOACs), 115
direct arteriovenous fistulas of the spine, 539–540
direct thrombin inhibitors, 169, 170, 176–177, 321
disseminated intravascular coagulation (DIC), 417, 546
distal protection devices, 151–152
dolichostenosis, 393–395
Donnan, Geoffrey, 6
Doppler, Christian, 86
Doppler sonography systems, 88–93
drowning
hypoxic brain injury, 374–375
drug abuse vasculopathy, 407–409
abuse of drugs intended for oral use, 408
amphetamine, 408
cocaine use, 408–409
heroin addiction, 407–408
infection as a complication of an addictive lifestyle, 408
drug addiction, 405
infection as a complication of an addictive lifestyle, 408
risk of infective endocarditis, 426
drug-eluting stents, 154
drug use
common locations of hemorrhages, 41
ICH related to, 482, 484–486
stroke related to, 526
dry edema, 47
dural arteriovenous fistulas of the spine, 538–539
dural arteriovenous malformations (DAVMs), 464–466
dural sinus thrombosis, 544
anticoagulant indications and timing, 174
Düret, Henri, 5
Duret hemorrhages, 49
dyslipidemia
risk factor for stroke, 574–575
Eales’s disease, 405
echocardiography, 7
Echoplanar Imaging
Thrombolytic Evaluation Trial (EPITHET), 159
eclampsia, 411–412
edema. See brain edema
edoxaban, 9, 176, 177, 321
EEG (electroencephalography), 115
likelihood of seizure in stroke patients, 150
Ehlers-Danlos syndrome, 324, 386, 393, 394, 440
ecosapentaenoic acid, 112, 169
Eisenhower, Dwight D., 2
elevated blood lipids
risk factor for stroke, 574–575
emboli
detection and monitoring using TCD ultrasound, 9
embolism, 20–22
definition, 19–20
distribution of embolic pathology, 38
recognition of the phenomenon, 3
See also brain embolism.
embolus protection devices, 151–152
EMBRACE trial, 320
encephalopathy, 328
endarterectomy, 150–151, 217
risks of carotid endarterectomy, 221–223
devascular endovascular photoacoustic reanimation (EPAR), 344
endovascular treatments
development of, 12–13
enteroviruses, 399
epidermal growth factor, 616
epidural hemorrhage, 23, 24
Epstein–Barr virus, 417, 418
epitibatide, 165, 179
erythrocytes
testing for abnormalities, 110–111
erythropoietin (EPO), 616
ERYTHROPOIETIC (EPO), 616
ESCAPE Trial, 163
Escourroule, Raymond, 1
essential mixed
cryoglobulinemia, 418
essential thrombocytemia, 415
état criblé condition, 301, 302
European Carotid Surgery Trial (ECST), 10, 226
European Cooperative Acute Stroke Study (ECASS), 155
European Stroke Prevention Studies (ESPS 1 and ESPS 2), 178
European Stroke Treatment with Ancrod trial (ESTAT), 160
Evidence-based medicine, 145
excitotoxin hypothesis, 181–182
exercise
influence on stroke risk, 578
Extend IA trial, 164
external carotid arteries (ECA), 26–28, 218
external counterpulsation (ECP), 169
extracranial to intracranial (EC–IC) bypass procedures, 10
extracranial vertebral arteries (ECVA’s)
dissections of the ECVA, 259
occclusion or severe stenosis in the neck, 256–259
occclusion or severe stenosis of the innominate artery, 252–256
occclusion or severe stenosis of the subclavian artery, 252–256
proximal aththerosclerotic ECVA disease, 256–259
subclavian steal syndrome, 252–256
Extremity Constraint Induced Therapy Evaluation (EXCITE) study, 188, 613
Fabrica, 3
Fabry disease, 132, 394, 419–419, 513
factor II, 170
factor V Leiden mutation, 45, 112, 416, 546
factor VIII, 112, 546
factor VIII autoantibodies, 416
factor VIII disorders, 416
factor X, 45, 170
factor Xa, 45
factor Xa inhibitors, 9, 169, 170, 176–177, 321
factor XI, 170
factor XII C46 T gene
polymorphism, 546
familial cerebral amyloid angiopathy (CAA), 135
FAST-MAG trial, 158, 165
fat embolism, 347–349
fatigue in stroke patients, 602
FBNI gene mutation, 133–134
Ferbert, Andreas, 11
ferritin
appearance on MRI, 80
fibrin, 45, 46, 111, 170, 176
fibrin dimer testing, 113
fibrinogen, 111–112, 170, 176
levels correlate with stroke risk, 581
lowering blood fibrinogen levels, 168–169
fibrinoid degeneration, 288
fibrinolytic system abnormalities, 416
fibromuscular dysplasia (FMD), 20, 386, 391–392, 440
fibrotic valve lesions, 173
Fields, William S., 9–10
Fisher, Charles Miller, 5–7, 9, 13, 18, 217, 287–288, 291
flow-diverting stents, 12

Index

© in this web service Cambridge University Press
www.cambridge.org
631
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>hypertension, 24, 37</td>
</tr>
<tr>
<td>blood pressure lowering targets, 582</td>
</tr>
<tr>
<td>effects on cerebral blood flow, 42</td>
</tr>
<tr>
<td>microbleeds caused by, 579</td>
</tr>
<tr>
<td>risk factor for stroke, 507–572</td>
</tr>
<tr>
<td>hypertrophic cardiomyopathy, 324</td>
</tr>
<tr>
<td>hypothermia</td>
</tr>
<tr>
<td>neuroprotective potential, 165</td>
</tr>
<tr>
<td>hypoxic-ischemic brain injury, 364</td>
</tr>
<tr>
<td>anatomy of, 367</td>
</tr>
<tr>
<td>basic critical care, 375–376</td>
</tr>
<tr>
<td>biochemical markers of injury, 371</td>
</tr>
<tr>
<td>borderzone infarcts and hemodynamic impairment, 372–373</td>
</tr>
<tr>
<td>cardiac arrest, 365–367</td>
</tr>
<tr>
<td>cardiac encephalopathy, 376–377</td>
</tr>
<tr>
<td>clinical examination, 369–370</td>
</tr>
<tr>
<td>clinical manifestations, 367–368</td>
</tr>
<tr>
<td>coma, 367–368</td>
</tr>
<tr>
<td>coronary angiography and revascularization, 366</td>
</tr>
<tr>
<td>critical care approach, 377–378</td>
</tr>
<tr>
<td>electrophysiological testing, 370–371</td>
</tr>
<tr>
<td>goal-directed hemodynamic optimization, 366–367</td>
</tr>
<tr>
<td>immediate post-resuscitation strategies, 366–367</td>
</tr>
<tr>
<td>minimally conscious state (MCS), 368</td>
</tr>
<tr>
<td>neurocritical care, 376</td>
</tr>
<tr>
<td>neuroimaging, 368–369, 371</td>
</tr>
<tr>
<td>neurological sequelae, 367–368</td>
</tr>
<tr>
<td>pathophysiology of brain injury, 364–365</td>
</tr>
<tr>
<td>prognostication after cardiac arrest, 369–372</td>
</tr>
<tr>
<td>targeted temperature management, 366</td>
</tr>
<tr>
<td>vegetative state, 368</td>
</tr>
<tr>
<td>iatrogenic bleeding disorders, 115</td>
</tr>
<tr>
<td>ibuprofen, 177</td>
</tr>
<tr>
<td>idiopathic hypertrophic subaortic stenosis, 324</td>
</tr>
<tr>
<td>imaging</td>
</tr>
<tr>
<td>cardiac evaluation, 104–105</td>
</tr>
<tr>
<td>catheter digital subtraction angiography, 104–105</td>
</tr>
<tr>
<td>establishing the age of, 84</td>
</tr>
<tr>
<td>mass effect caused by, 84</td>
</tr>
<tr>
<td>presence of edema, 84</td>
</tr>
<tr>
<td>presence of other lesions, 84</td>
</tr>
<tr>
<td>size of, 83</td>
</tr>
<tr>
<td>vascular territory involved, 83</td>
</tr>
<tr>
<td>infections and stroke risk, 416, 581</td>
</tr>
<tr>
<td>role in cerebral venous thrombosis, 545</td>
</tr>
<tr>
<td>infectious vasculitides, 397–400</td>
</tr>
<tr>
<td>infective endocarditis, 324</td>
</tr>
<tr>
<td>source of brain emboli, 326–328</td>
</tr>
<tr>
<td>inflammation</td>
</tr>
<tr>
<td>and blood vessel damage, 581</td>
</tr>
<tr>
<td>inflammatory bowel disease, 546</td>
</tr>
<tr>
<td>inflammatory disorders, 386–389</td>
</tr>
<tr>
<td>and stroke risk, 416</td>
</tr>
<tr>
<td>innominate arteries</td>
</tr>
<tr>
<td>occlusion or severe stenosis, 252–256</td>
</tr>
<tr>
<td>insula of Reil infarction, 237–239</td>
</tr>
<tr>
<td>insulin resistance</td>
</tr>
<tr>
<td>risk factor for stroke, 573–574</td>
</tr>
<tr>
<td>INTERACT 2 trial, 184</td>
</tr>
<tr>
<td>internal capsule signs and symptoms of ICH, 487–491</td>
</tr>
<tr>
<td>internal carotid arteries (ICA), 26–28</td>
</tr>
<tr>
<td>asymptomatic patients with ICA disease in the neck, 226–228</td>
</tr>
<tr>
<td>atherosclerotic ICA disease in the neck, 217–221</td>
</tr>
<tr>
<td>brain imaging findings in patients with ICA disease, 221–223</td>
</tr>
<tr>
<td>carotid artery clots, 226</td>
</tr>
<tr>
<td>carotid siphon disease, 233</td>
</tr>
<tr>
<td>carotid artery disease, 221–223</td>
</tr>
<tr>
<td>carotid siphon disease, 233–239</td>
</tr>
<tr>
<td>choice of treatment for ICA disease, 221–223</td>
</tr>
<tr>
<td>complete occlusion of the ICA in the neck, 223–225</td>
</tr>
<tr>
<td>dissections in the neck, 386–389</td>
</tr>
<tr>
<td>extracranial carotid artery dissections, 228–230</td>
</tr>
<tr>
<td>intracranial dissections, 233, 390</td>
</tr>
<tr>
<td>intracranial ICA disease, 230–232</td>
</tr>
<tr>
<td>plaque disease of the ICA in the neck with slight or moderate stenosis, 226</td>
</tr>
<tr>
<td>risks of carotid endarterectomy, 221–223</td>
</tr>
<tr>
<td>severe stenosis of the ICA in the neck, 225–226</td>
</tr>
<tr>
<td>sites of atherosclerotic narrowing, 36–37</td>
</tr>
<tr>
<td>top of the carotid artery, 228</td>
</tr>
<tr>
<td>carotid artery injection, 323</td>
</tr>
<tr>
<td>International normalized ratio (INR), 112, 172</td>
</tr>
<tr>
<td>International Stroke Genetics Consortium (ISGC), 137, 139</td>
</tr>
</tbody>
</table>
International Stroke Trial (IST), 173, 174
International Study of Unruptured Intracranial Aneurysms, 454
International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT), 545
intracerebral hemorrhage (ICH), 23, 24
blood abnormalities, 115
clinical course, 477–480
decreased level of consciousness, 480
detecting vascular lesions, 109
diagnosis, 499–500
distribution of brain pathology, 41
distribution of pathology, 38
drainage pathway of the hematoma, 85
epidemiology, 477
etiologies, 480–486
amphetamine use, 484–485
bleeding diathesis, 483–484
cerebral amyloid angiopathy (CAA), 486
cocaine use, 485
cough and cold remedies, 485–486
drug-induced ICH, 484–486
frequencies of common etiologies, 486
hypertension, 480–483
intravenous use of drugs intended for oral use, 486
phenytoin (Dilantin), 485–486
trauma, 486
etiology suggested by the location, 84
genetic factors, 135–136, 137, 139
headache, 480
history of treatment approaches, 477
hydrocephalus, 85
imaging, 84–85, 109
incidence, 439, 477
indications of hematoma enlargement, 85
mass effect, 84–85
pathophysiology, 48–49
prognosis, 500
reducing or limiting the size of, 184–186
seizures, 480
signs and symptoms, 477–480
signs and symptoms by location, 486–499
caudate nucleus, 491
cerebellum, hemorrhages, 497–499
internal capsule, 487–491
lateral basal ganglia, 487–491
lobar hemorrhages, 492–494
pontine hemorrhages, 495–497
primary intraventricular hemorrhages, 494–495
putamen, 487–491
thalamus, 491–492
size of the hematoma, 84–85
spot sign on CTA images, 85
treatment medical treatment, 500–501
surgical considerations, 501–504
vomiting, 480
intracranial arterial dissections, 390
intracranial artery angioplasty/stenting, 153–154
intracranial branch atheromatous disease, 288–291
intracranial vertebral arteries (ICVs)
ICV disease, 259–266
intravascular lymphoma, 417–418
intravenous magnesium efficacy in stroke (IMAGES), 301
intraventricular hemorrhage signs and symptoms, 494–495
ischemia causes of brain ischemia, 19–23
distribution of brain pathology, 39–40
factors affecting tissue survival, 46–47
local brain effects, 42–43
normal brain metabolism and blood flow, 41–42
pathology of stroke, 19–23
pathophysiology, 41–44, 46–47
ischemic penumbra, 43
ischemic stroke blood abnormalities, 110–114
genetic risk factors, 137–138
multimodal imaging, 97–101
isosuprime, 167
Joint Study of Extracranial Arterial Occlusions, 9–10
juvenile lesions of the spine, 539–540
Kalkar, Jan, 3
Kawasaki disease, 400
kidney disease
link with stroke risk, 581
Kohlmeier–Degos syndrome, 407
Korsakoff’s syndrome, 277, 373
Kubik, Charles, 6
laboratory tests cause of the brain lesion, 82
lumbar puncture, 82
sequence of diagnostic questions, 78
stroke mechanism investigation, 82
lacunar hypothesis, 287
lacunar infarction, 287
cognitive impairment, 298
diagnostic investigations, 298–299
frequency of lacunar stroke, 287
general clinical findings, 291–292
genetic factors, 129–131
hemispheric lesions within the anterior circulation, 292–293
imaging findings, 298–299
location of lesions and clinical syndromes, 292–298
medulla, 293–295
midbrain, 295
pathogenesis, 303–304
pathology, 287–291
pons, 293–295
posterior circulation, 293–298
thalamus, 295–298
stroke mechanism investigation, 82
lacunar syndrome, 287
stroke frequency of, 287
treatment, 299–301
See also chronic penetrating artery disease.
lacune definition, 287
large artery occlusive disease anterior circulation, 217–244
large artery thrombosis anticoagulant indications and timing, 174–176
large vessel occlusive disease posterior circulation, 252–280
lateral basal ganglia signs and symptoms of ICH, 487–491
lateral sinus thrombosis, 549–552
Lausanne Stroke Registry, 84, 239, 279–280, 314, 336, 596
Lemierre syndrome, 400, 545
Lenin, Vladimir, 1
leukemia, 111, 415
leukocoria, 302
Leukoaraiosis and Disability (LADIS) Study, 302
leukocytes testing for abnormalities, 111
levodopa, 617
Libman–Sacks endocarditis, 173, 401
lipoaluminosis, 287–288, 289, 481
lipoprotein-associated phospholipase A2 (LpPLA2), 581
lipoprotein levels in the blood, 112
Listeria monocytogenes infection, 398
liosidase, 189
livedo reticularis and strokes, 113
lobar hemorrhages signs and symptoms, 492–494
Locomotor Experience Applied Post-Stroke (LEAPS) trial, 613
Loeys–Dietz syndrome, 386, 393
lotrifiban, 179–180
lovastatin, 184
lumbar puncture
stroke mechanism investigation, 82
lupus anticoagulant (LA), 113, 546
lupus erythematosus, 173
lyme borreliosis, 398
lymphomatoid granulomatosis, 417
lysergic acid diethylamide (LSD), 485
lysosomal storage disorders, 132
macular sparing, 275
magnesium sulfate, 165
malaria infection of the CNS, 400
malayan pit-venom extract, 112, 160
malignant atrophic papulosis, 407
malignant MCA infarction, 595
Malpighi, Marcello, 1
mannitol, 186–187
marantic non-bacterial thrombotic endocarditis (NBTE), 329–331
Marfan’s syndrome, 133–134, 324, 386, 393, 440, 513
Marie, Pierre, 287, 292, 301
mass effect, 22
brain shift caused by, 48–49
caused by infarcts, 84
due to intracerebral hemorrhage, 84–85
management, 346
MATCH trial, 179
mechanical devices used for stroke interventions, 12–13
medical complications of stroke, 599–600
medical figures who had strokes, 1–2
medulla, 293–295
MELT trial, 160
lipid abnormalities, 287–288, 289, 481
lipoprotein-associated phospholipase A2 (LpPLA2), 581
lipoprotein levels in the blood, 112
Listeria monocytogenes infection, 398
liosidase, 189
livedo reticularis and strokes, 113
lobar hemorrhages signs and symptoms, 492–494
Locomotor Experience Applied Post-Stroke (LEAPS) trial, 613
Loeys–Dietz syndrome, 386, 393
lotrifiban, 179–180
lovastatin, 184
lumbar puncture
stroke mechanism investigation, 82
lupus anticoagulant (LA), 113, 546
lupus erythematosus, 173
lyme borreliosis, 398
lymphomatoid granulomatosis, 417
lysergic acid diethylamide (LSD), 485
lysosomal storage disorders, 132
macular sparing, 275
magnesium sulfate, 165
malaria infection of the CNS, 400
malayan pit-venom extract, 112, 160
malignant atrophic papulosis, 407
malignant MCA infarction, 595
Malpighi, Marcello, 1
mannitol, 186–187
marantic non-bacterial thrombotic endocarditis (NBTE), 329–331
Marfan’s syndrome, 133–134, 324, 386, 393, 440, 513
Marie, Pierre, 287, 292, 301
mass effect, 22
brain shift caused by, 48–49
caused by infarcts, 84
due to intracerebral hemorrhage, 84–85
management, 346
MATCH trial, 179
mechanical devices used for stroke interventions, 12–13
medical complications of stroke, 599–600
medical figures who had strokes, 1–2
medulla, 293–295
MELT trial, 160
memantine, 615
meningitis, 398, 399
in endocarditis patients, 328
meningocerebral hemorrhage, 443
Menkes disease, 19
metabolic disorders in stroke patients, 600
metabolic syndrome risk factor for stroke, 573–574
methemoglobin appearance on MRI, 80
methylphenidate, 408, 486
therapeutic use, 615
Meyer, John Sterling, 11
Michael Reese Stroke Registry, 57–60, 63, 314, 477, 483
microalbuminuria link with stroke risk, 581
mucosa, 481
microangiopathy of the brain, ear, and retina, 405–406
microatherosomas, 20, 37
microbleeds, 327–328, 395
appearance on imaging, 579 imaging, 79–80
indication of stroke risk, 579
microcirculatory bed changes caused by ischemia, 46–47
midbrain lacunar infarction, 295
middle cerebral arteries (MCA), 26–28
atherosclerotic narrowing, 36
deep involvement of the MCA territory, 236–237
insula of Reil infarction, 237–239
intracranial dissections, 390
mainstream occlusion with total infarction of the MCA territory, 237
malignant MCA infarction, 595
occlusion of the inferior division of the MCA, 236
occlusion or severe stenosis of the MCA stem or its major upper or lower trunks, 233–235
occlusion or stenosis of the upper division of the MCA, 235
segmental infarction in the MCA territory, 237
migraine, 168, 218, 386, 387, 409–411
minimally conscious state (MCS), 368
mirror neurons, 617
mitochondrial DNA mutations, 134–135
mitochondrial myopathy, encopelaphathy, lactic acidosis, and stroke-like episodes (MELAS), 134–135, 418, 512
mitral annulus calcification (MAC), 173
source of brain emboli, 325
mitral valve prolapse (MVP), 173
source of brain emboli, 324–325
mixed cryptoglobulinemia, 401
MMPI2 gene, 137, 138
Mohr, Jay P, 6
Moniz, Egaz, 7
Morgagni, Giovanni Battista, 3–4
Mori, Etsuko, 11
movement observation therapies, 617
 moyamoya syndrome, 167,
412–414, 511, 512
MR angiography (MRA), 8, 82,
95–96, 217
MR spectroscopy (MRS), 8, 109
MR venography (MRV)
cerebral venous sinus thrombosis, 97
MRI (magnetic resonance imaging), 7–8
appearance of hemoglobin derivatives, 80
fMRI (functional MRI), 109
multimodal protocols, 97–101
perfusion imaging, 97
scans of vascular lesions, 93–94
stroke mechanism investigation, 79–82
MTHFR deficiency and stroke risk, 114
ocular adenocarcinoma, 416
Muscar infection, 398–399
multiple myeloma, 112
mumps, 399
mycobacterium tuberculosis, 398
mycoplasma pneumonia infection, 399
myotic aneurysms, 327–328,
399, 454
myocardial infarction source of brain emboli, 331–332
myocardio pathies source of brain emboli, 332
nadaroparin, 174
NASCET study, 226
nasogastric feeding tubes, 600
National Health and Nutrition Examination Survey (NHANES), 577
neck artery angioplasty/stenting, 151–153
neonatal stroke, 513–516
arterial and venous strokes, 515–516
hypoxic-ischemic insults, 513–514
presumed perinatal ischemic stroke, 515
neoplastic angiogenesis, 47
neoplastic disorders vasculopathy related to, 417–418
nephrotic syndrome, 546
neurocysticercosis, 511, 525
neurofibromatosis type 1 (NF1), 419, 513
Neuroloer catheter, 169
neurological complications of stroke, 594–597
neurological sequelae of hypoxic-ischemic brain injury, 368
neuroprotection increasing the brain’s resistance to ischemia, 181–183
potential of statins, 183–184
neurosyphilis, 525
New England Medical Center Posterior Circulation Registry, 254, 256, 257, 263, 266, 279–280
nitric acid, 167
nimodipine, 168
NINDS study, 11, 156, 157
NINJ2 gene, 137, 138
nitroglycerin, 165
Nixon, Richard, 2
non-atherosclerotic vasculopathies
variety of, 386
non-bacterial thrombotic endocarditis (NBTIE), 329–331
non-pyramidal hemimotor syndrome, 293
non-steroidal anti-inflammatory drugs, 177
non-thrombotic (marantic) endocarditis, 173
North American Symptomatic Carotid Endarterectomy Trial (NASCET), 10, 224, 582
North Manhattan Stroke Study, 578
Northern Manhattan Study, 581
NOTCH gene mutations, 129–130
Nurses Health Study, 577, 578
nutritional disorders in stroke patients, 600
nystagmus, 72
obesity, 332
risk factor for stroke, 573–574
oculoplethysmography, 109
omega-3 fatty acids, 169
omega-3 fish oil, 112
ophthalmodynamometry, 109
optic ataxia, 278
oral contraceptives association, 418–419
orofacial pain, 152
osteogenesis imperfecta, 136, 201
oral contraceptives
OSL 10172, 174, 175
Osler, Sir William, 1, 5
Osler–Weber–Rendu disease, 5, 420–421
osteogenesis imperfecta, 136, 324, 386
osteopenia in stroke patients, 601–602
osteoporosis in stroke patients, 601–602
otitic hydrocephalus, 544
oxygen free radicals, 42, 43
oxyhemoglobin appearance on MRI, 80
P-ANCA granulomatosis with polyangiitis, 401
papaverine, 161, 167
paradoxical embolism, 20
source of brain emboli, 333–336
paramyxoviruses, 399
parasitic infections as cause of vasculitis, 400
parenchymal hemorrhage, 24
paroxysmal nocturnal hemoglobinuria (PNH), 415, 546
parvovirus, 399
Pasteur, Louis, 1, 567
patent foramen ovale, 20, 173–174
and stroke risk, 333–336
Patent Foramen Ovale in Cryptogenic Stroke (PICSS), 173
pathology of stroke, 19
damage caused by ischemia, 23
embolism, 19–22
epidural hemorrhage, 23, 24
hemorrhage, 19, 23–24
infection, 23
influence on treatment, 25
intracerebral hemorrhage (ICH), 23, 24
ischemia, 19–23
mechanisms of cerebrovascular damage, 19–24
parenchymal hemorrhage, 24
subarachnoid hemorrhage (SAH), 23
subdural hemorrhage, 23, 24
systemic hypoperfusion, 19–20, 22
thrombosis, 19–20
venous hypertension, 22–23
venous occlusions, 22–23
pathophysiology of stroke, 19
arterial occlusion, 43–44
brain shifts and herniations, 48–49
cogulation system activation, 44–46
Duret hemorrhages, 49
factors affecting ischemic tissue survival, 46–47
first three weeks after vascular occlusion, 47–48
increased intracranial pressure, 47
intracerebral hemorrhage (ICH), 48–49
ischemia, 41–44
local brain effects of ischemia, 42–43
normal brain metabolism and blood flow, 41–42
reaction to the occlusive process, 43–44
secondary hemorrhages, 49
subarachnoid hemorrhage (SAH), 50
thrombus formation, 44–46
PDE4D gene polymorphisms, 116
pediatric stroke
approach to diagnosis, 512–513
arterial and venous strokes in neonates, 515–516
clinical presentations and features, 512
compared to adult stroke, 511
differences in evaluation, 526–527
dural sinus and venous occlusions, 521–522
etiological variations related to age, 511
hemorrhagical strokes in children, 517–518
history of recognition and treatment, 517
hypoxic-ischemic insults in neonates, 513–514
incidence, 511, 517
ischemic strokes in children, 518–521
locations of lesions, 511–512
neonatal stroke, 513–516
prevalence of hemorrhagical stroke, 511
prevalence of particular etiologies, 511
prognosis, 513
penetrating artery disease. See chronic penetrating artery disease; lacunar infarction; lacunar stroke
pentazocine, 408, 486
pentoxifylline, 169
Penumbra system, 161
percutaneous endoscopic gastrosomy (PEG) tubes, 600
perfluorochemicals, 169
perfusion imaging, 97, 100–101
perinatal stroke, 511
peripheral nerve injuries in stroke patients, 601
peripheral vascular disease risk factor for stroke, 575–576
Pessin, Michael, 11
PET (positron-emission tomography), 101–104
petrolus sinuses, 33, 34
PHACTR1 gene, 138
PHANTOM-S trial, 158
pharmacological agents which retard recovery, 615
pharmacological therapies to enhance recovery, 615
phenytoiclydine (PCP, angel dust) as cause of ICH, 485
phenylbutazone, 177
phenylephrine, 150, 486
phenylpropanolamine (PPP) risk of ICH, 485–486
phlebothromboses, 45
phosphodiesterase inhibitors, 167, 177–178
Physicians Health Study, 571, 578
PITX2 gene, 137–138
plasmaspheresis techniques, 168–169
plasmolin, 45, 154
plasmogin, 45
plasmogin deficiency, 546
Plasmodium falciparum infection of the CNS, 400
platelet function modifiers antiplatelet therapies for specific vessel sites, 180
aspirin, 177
cilostazol, 177–178
clopogedril, 178–179
dipyridamole, 177–178
GP IIb/IIIa antagonists, 179–180
phosphodiesterase inhibitors, 177–178
thienopyridines, 178–179
ticlodipine, 178–179
platelets
testing for abnormalities, 111
PMF1 gene, 137, 139
pneumococcal infection, 551
pneumonia
complication in stroke patients, 599–600
Pocock, Klaus, 11
POINT trial, 179
polyarteritis nodosa, 399, 401
polycystic kidney disease, 440
polychytoloma, 170, 415, 417
polychytoloma vera, 546
polypharmacy in stroke patients, 190, 615
pons
lacunar infarction, 293–295
pineate hemorrhage signs and symptoms, 495–497
post-cardiac arrest encephalopathy. See cardiac arrest; hypoxic-ischemic brain injury
posterior cerebral arteries (PCA), 26–28, 31, 244
intracranial dissections, 390
occlusion or severe stenosis, 273–275
cognitive and behavioral abnormalities, 276–277
motor abnormalities, 275–276
somatosensory abnormalities, 275
upper and lower calcarine bank lesions, 277–279
visual field abnormalities, 275
posterior circulation, 28–29
large vessel occlusive disease, 252–280
posterior circulation ischemia differential diagnosis, 279–280
posterior inferior cerebellar arteries (PLICAs), 31
posterior reversible encephalopathy syndrome (PRES), 411–412
postpartum angiopathy, 409
postpartum cerebral venous thrombosis (CVT), 545
postpartum risk of stroke, 577
power Doppler, 89–90
prasugrel, 169
pravastatin, 184
praziquantel, 400
precaeplimsia/eclampsia, 411–412
pregnancy risk of cerebral venous thrombosis (CVT), 545
risk of stroke, 577
Premarin, 577
prevention of stroke
abdominal imaging, 579
alcohol risk factor, 575
aortic conditions, 580
benefits of exercise, 578
biomarkers for vascular disease, 580–581
blood pressure lowering targets, 582
cardiac conditions, 580
cervico-cranial and intracranial arterial abnormalities, 580
coronary artery atherosclerosis risk factor, 575–576
demographic risk factors that are not modifiable, 567
diabetes risk factor, 573–574
dyslipidemia risk factor, 574–575
effects of hormone replacement therapy, 577–578
evaluation of stroke risk, 568–569
future developments, 583
genetic conditions related to vascular disease, 581–582
heart disease risk factor, 572–573
hematological abnormalities, 580
high stroke-mortality regional clusters, 578
hormonal risk factors, 577–578
hypertension risk factor, 570–572
identifying people at risk, 582
importance of beginning at an early age, 569–570
importance of prevention, 567
influence of geographic location, 578
insulin resistance risk factor, 573–574
metabolic syndrome risk factor, 573–574
obesity risk factor, 573–574
oral/hormonal contraceptive use risk factor, 577
peripheral vascular disease risk factor, 575–576
pregnancy and postpartum risk of stroke, 577
presence of brain microbleeds, 579
presence of unexpected brain infarcts, 578–579
presence of white matter hyperintensities, 578
prevention strategies, 567–569
primary prevention, 582
public education, 567, 582
retinal examination, 579
risk associated with sedentary lifestyle, 578
risk factors for stroke, 569–578
secondary (recurrent) prevention, 582–583
silent strokes, 578–579
smoking risk factor, 574
statin therapy, 183–184, 582
subclinical-cervico-cranial hematological lesions, 579
subclinical indications of vascular disease and vascular risks, 578–580
transient ischemics attack (TIA) risk factor, 576–577
Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial, 300 primary angiitis of the CNS (PACNS), 403–404

Index

© in this web service Cambridge University Press www.cambridge.org
spinal vascular malformations, 538–540
dural (type I), 538–539
intradural (type II), 539–540
spine
cavernous angioma, 539–540
direct arteriovenous fistulas, 539–540
glomus lesions, 539–540
juvenile lesions, 539–540
Stalin, Joseph, 1
Staphylococcus aureus acute endocarditis, 328
Staphylococcus aureus infection, 551
statins, 568, 582
role in stroke prevention and treatment, 183–184
stem cell therapies, 615–616
stem cell transplantation, 188
stent retrievers, 162, 163–165
stenting, 151–154, 161, 217
Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMPTRIS) trial, 153, 232, 266
Stenting and Angioplasty with Protected in Patients at High Risk for Endarterectomy (SAPPHIRE) study, 152
Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA) trial, 259
stents, 12–13
STICH 1 trial, 185
Stippefeld, Nicole, 551
straight sinus thrombosis, 549–551
streptococcal infection, 551
Streptococcus pneumoniae, 114
streptokinase, 114, 155, 160
stress ulcers, 601
stroke
annual worldwide mortality rates, 1 as model of brain and vascular disease, 13
costs of, 1
definition, 19
disability caused by, 1 heterogeneous nature, 19 in historical and medical figures, 1–2
incidence worldwide, 1 personal tragedy of, 2
stroke belt phenomenon, 578
stroke care, 13
stroke centers, 149
delivery of patients to, 157–158
development of competent centers, 157–158
Stroke Data Bank, 314, 336, 477
stroke-like migraine attacks after radiation therapy (SMART) syndrome, 410–411
stroke mechanism comparison between CT and MRI investigations, 80–82
CT investigation, 78–79
lumbar puncture investigation, 82
MRI investigation, 79–80
stroke nurses, 8–9
Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study, 301
Stroke Prevention in Reversible Ischemia Trial (SPRIT), 172
stroke progression or recurrence, 594–595
stroke registries, 8
stroke risk-factor score, 582
stroke specialists, 8–9
Stroke Treatment with Anycrod Trial (STAT), 160
study, 8–9, 149
Study of Prevention of Small Subcortical Strokes (SPS3) trial, 300
Subacute Therapy with Amphetamine and Rehabilitation for Stroke (STARS) study, 615
subarachnoid hemorrhage (SAH), 23, 168
arteriovenous malformations (AVMs), 454–455
assessing the extent of bleeding, 85–86
blood abnormalities, 115 causes, 439
convex subarachnoid hemorrhage, 85
CT findings, 79
distribution of pathology, 38–39
hydrocephalus, 86
imaging, 85–86
imaging of vascular lesions, 109–110
incidence, 439
location of the blood, 85
lumbar puncture investigation, 82
magnetic resonance imaging (MRI), 80
pathophysiology, 50
regions of infarction, 86
spinal, 540
symptoms, 439
See also aneurysmal SAH.
subclavian arteries, 29
occlusion or severe stenosis, 252–256
subclavian steal syndrome, 252–256
subcortical arteriosclerotic encephalopathy, 301
subdural hemorrhage, 23, 24
suction thrombectomy, 161–162
superior cerebellar artery (SCA), 31
superior sagittal sinuses, 33
surgical advances, 9–11
surgical endarterectomy, 150–151
Sussac syndrome, 405–406, 512, 513
susceptibility-weighted imaging (SWI), 79–80
swallowing abnormalities in stroke patients, 599–600
SWIFT PRIME trial, 164
Symonds, Sir Charles, 544
synthetic heparin
pentasaccharides, 170
synthetic thrombolytics, 170
syphilis, 324, 398
syphilis testing, 113
systemic sclerosis, 402
systemic hypoperfusion, 22
definition, 19–20
systemic hypotension, 22
systemic lupus erythematosus (SLE), 111, 328–331, 401, 513, 546
systemic sclerosis, 402
systemic vasculitides, 401–402
Syphilitic Hypertension in the Elderly Program (SHEP), 571
tadalaafil (Cialis), 486
Takeyasu’s arteritis, 20, 114, 404
takotsubo cardiomyopathy, 332
Talwin, 408
telangiectases (telangiectasias), 456
telerhabilitation, 614
temporal arteritis, 37, 114, 403
tenecteplase, 161
Terson syndrome, 442
talamus
lacunar infarction, 295–298
signs and symptoms of ICH, 491–492
Thibault, George, 145
thienopyridines, 178–179
Thrombectomy
REVascularization of large Vessel Occlusions in acute ischemic stroke (TREVO) 2 trial, 162
thrombi prevention of formation and propagation, 169–170
thrombin, 45, 111, 170
thrombin inhibitors, 9, 176–177
thrombogenesis, 404
thromboocyteopenia, 113, 415
heparin induced, 171
thromboembolism, 111, 170, 546
thrombolysis, 97–99, 154–157
development of techniques, 11–12
eye early observational studies, 144–155
eye early studies, 154
effects of FDA approval of rt-PA, 157
improving IV thrombolysis, 160
multiple neuroprotective and thrombolytic combinations, 165
potential benefits of TCD monitoring, 165–166
present recommendations for, 166–167
randomized trials of IA thrombolysis, 156–157
randomized trials of IV thrombolysis, 155–156
rationale for, 154
selection of candidates for, 159–160
thrombolytics, 160–161
anycrod, 160
desmoteplase, 161
rt-PA, 154–155, 157
streptokinase, 154, 155, 160
tenecteplase, 161
urokinases, 155, 160
thrombosis, 20
definition, 19–20
distribution of pathology, 36–38
thrombosis pathophysiology adequacy of collateral circulation, 46
brain edema, 47
changes within the obstructing vascular lesion, 46
factors affecting tissue survival, 46–47
first three weeks after vascular thrombosis, 47–48
increased intracranial pressure, 47
resistance within the microcirculatory bed, 46–47
serological factors, 46
state of the systemic circulation, 46
thrombus formation, 44–46
thrombotic thrombocytopoenic purpura (TTP), 111, 401–402
ticlopidine, 169, 178–179
Ticlopidine–Aspirin Stroke Study (TASS), 178
tifiroban, 165, 179
iPA (tissue plasminogen activator), 45, 46, 157, 169
transcranial direct current stimulation (tDCS), 189, 615
transcranial Doppler (TCD) ultrasound, 7, 90–91, 312
embolus detection and monitoring, 91–92
studying cranial venous structures, 93
to enhance perfusion, 165–166
transcranial magnetic stimulation (TMS), 189, 614–615
transesophageal echocardiography (TEE), 8, 105–108
transient cerebral arteriopathy, 512
transient ischemic attacks (TIAs), 3, 6, 217, 218, 387–388
diagnostic and prognostic features, 61–63
magnetic resonance imaging (MRI), 81–82
risk factor for stroke, 576–577
spinal TIAs, 536, 538–539
transplant patients
CSF infection risk, 398–399
transhural echocardiography (TEE), 105–106
transverse sinuses, 33
traumatic intracerebral hemorrhage (ICH), 486
treatment
coordination of acute and long-term care, 612–613
treatment of ischemic stroke, 149–184
angioplasty and/or stenting, 151–154, 161
anticoagulants, 170–177
antiplatelet therapies for specific vessel sites, 180
approach to treatment, 149
catherer-based mechanical thrombectomy, 161, 162–163
clinician approach to treatment, 190
clot retrieval devices, 161, 162–165
comments and rules for clinicians, 190
controlling position and activity, 149–150
improving IV thrombolysis, 160
increasing blood flow in the collateral circulation, 167–169
increasing perfusion in the ischemic-zone capillary bed, 167–169
increasing the brain’s resistance to ischemia, 181–183
intracranial artery angioplasty/stenting, 153–154
local reconstruction, 150–151
managing blood pressure, 150
managing blood volume, 150
maximizing cardiac output, 150
multiple neuroprotective and thrombotic combinations, 165
neck artery angioplasty/stenting, 151–153
neuroprotection potential of statins, 183–184
neuroprotection strategies, 181–183
platelet function modifiers, 177–180
present recommendations for thrombolysis, 166–167
prevention of clot formation, propagation and embolism, 169–170
promoting recovery, 188–190
range of endovascular mechanical interventions, 161
reducing blood viscosity, 168–169
reperfusion strategies, 150–157
reperfusion using mechanical techniques, 161–165
reperfusion using multiple techniques, 165
selection of candidates for thrombolysis, 159–160
strategies for earlier treatment, 158
suction thrombectomy, 161–162
surgical endarterectomy, 150–151
surgically bypassing regions of blockage, 167
thrombolyis, 154–157, 160, 166–167
thrombolytics other than rt-PA, 160–161
use of ultrasound to enhance perfusion, 165–166
use of vasodilating agents, 167–168
volume expansion, 168
consciousness, 189–190
approach to treatment, 145
close examination of the eyes, 69–70
factors to enhance perfusion, 186–188
delivery of patients to stroke centers, 157–158
development of competent medical centers, 157–158
doctor-to-needle time, 157–158
evidence-based medicine, 145
general care, 148–149
influence of stroke mechanism, 25
reducing or limiting the size of ICH, 184–186
results from randomized clinical trials, 145
stroke centers, 149
stroke units, 149
treating availability of personnel and technology, 147
blood abnormalities, 146
characteristics of the brain lesion, 146–147
general therapeutic strategies, 147
hematological disorders, 146
mechanisms and pathophysiology of stroke, 146
nature of the vascular lesion, 146
pace of the stroke, 147
presence of other medical conditions, 146
psychological factors, 146
reasons for worsening in stroke patients, 146–147
reversibility of the brain lesions, 146–147
risk for further ischemia, 146–147
socioeconomic factors, 146
specific problems in individual patients, 147
TREX1 gene mutations, 131
Trial of ORG 10172 in Acute Stroke Treatment (TOAST), 174
trifusal, 169
trigeminal nerve stimulation association with ICH, 482
Trypanosoma cruzi infection, 174
tuberculous meningitis, 398, 511
tumor embolism, 161
ulcerative colitis, 416, 546
ultrasound, 7, 8, 217
urticaria, 177
urokinases, 155, 160, 165
vascular Ehlers-Danlos syndrome (vEDS), 133
vascular endothelial growth factor (VEGF), 616
vascular lesions
cardiac embolus risk evaluation, 105–109
cardiogenic embolism, 66
catheter digital subtraction angiography, 104–105
CT angiography (CTA), 96–97
CT scans, 93
findings of examination of the heart, 66
findings from examination of the vascular system, 66–69
general and neurological examination, 66–70
imaging cerebral venous sinus thrombosis, 97
imaging in intracerebral hemorrhage, 109
imaging in subarachnoid hemorrhage, 109–110
localization and detection, 66–70
MR angiography (MRA), 95–96
MRI scans, 93–94
multimodal imaging, 97–101
newer imaging techniques, 109
perfusion imaging, 97
PET scans, 101–104
SPECT scanning, 101
tests to identify location and characteristics, 66–110
ultrasound imaging, 86–93
xenon CT, 101
vascular malformations, 454–455
arteriovenous malformations (AVMs), 455
cavernous angiomas, 455–456
classification, 453
clinical symptoms and signs, 458–460
developmental venous anomalies (DVAs), 455
diagnosis, 460
dural arteriovenous malformations (AVMs), 464–466
diagnosis, 460
location of the various malformations, 458
medical treatment, 464
pathogenesis of AVMs, 456–467
prognosis for AVMs, 461
prognosis for cavernous angiomas, 461–462
Index

prognosis for developmental venous anomalies (DVAs), 462
radiotherapy, 463
surgical treatment, 462–463
telangiectases (telangiectasias), 456
treatment, 462–464
vasculitis
as cause of stroke, 396
bacterial infections, 397–399
caused by infections, 397–400
fungal infections, 397–399
parasitic infections, 400
systemic vasculitides, 401–402
viral infections, 399–400
vasculopathy
caused by drug abuse, 407–409
vasoconstriction syndromes, 409–411
vasodilating agents, 167–168
vasogenic edema, 47
vegetative state, 368
vein of Galen, 34
veins of Labbé, 22, 34
veins of Rosenthal, 34
veins of Treblard, 34
venous and dural sinus anatomy, 31–34
venous hypertension, 22–23
venous occlusions, 22–23
vesicular stasis retinopathy, 219, 579
vertebral arteries, 28–31
dissections in the neck, 389–390
intracranial dissections, 390
See also extracranial vertebral arteries; intracranial vertebral arteries.
vertebrobasilar disease, 252
Vesalius, Andreas, 3
viral causes of vasculitis, 399–400
Virchow, Rudolph, 4–5
VISSIT trial, 154
visual field abnormalities, 275
transient blindness, 218, 231
visual field defects
therapies for, 617
visual neglect, 275, 277
vitamin K, 45
VKORCI gene, 172
Vogt–Koyanagi–Harada syndrome, 406
von Willebrand disease, 416
Waldenström’s macroglobulinaemia, 112, 417
warfarin, 9, 45, 115, 169, 170, 171, 172, 174, 177, 320–321
Warfarin Aspirin Recurrent Stroke Study (WARSS), 9, 173, 175, 300
Warfarin–Aspirin for Symptomatic Intracranial Disease (WASID) trial, 9, 175, 176, 180, 232, 239, 266, 581
watershed regions, 22, 39–40
spinal cord, 535
Weber’s syndrome, 295, 441
Wegener’s granulomatosis, 401, 546
Wefer, Johann Jakob, 3
wet edema, 47
white blood cell (WBC) count
correlation with stroke risk, 581–582
white clots, 43–44, 46, 70, 111, 168, 169–170
Willis, Thomas, 3
Wilson, Woodrow, 1
Women’s Estrogen Stroke Trial (WEST), 9, 173, 175, 300
Women’s Health Initiative (WHI), 577
Women’s Health Initiative Memory Study in Younger Women (WHIMS), 577
Women’s Health Study, 575
World Federation of Neurological Surgeons Scale (WFNS), 443
World Health Organization (WHO) international Classification of Functioning, Disability, and Health (ICF), 609–610
Wren, Christopher, 3
xenon CT, 101
ximelagatran, 176
X-linked lymphoproliferative disease (XLP), 418
Yasargil, Gazi, 10
young adult stroke
approach to diagnosis, 512–513
clinical presentations and features, 512–526
cases for specific etiologies, 522–526
compared to older adult stroke, 511
differences in evaluation, 526–527
etiological variations related to age, 511
incidence, 511
locations of lesions, 511–512
prevalence of hemorrhagic stroke, 511
prevalence of particular etiologies, 511
prognosis, 513
studies, 522
Zeumer, Hermann, 11
ZFHX3 gene, 137–138